|
|
 |
|
Viewing report
|
|
|
|
Systems Biology - Key to Unlocking the Value within the Omics Revolution
Drug and Market Development Publishing, Jan 2004, Pages: 200
Market projections for systems biology products and services are expected to grow at an annual compound rate of 66% to $785 million by 2008.
The recent availability of masses of omic (genomic, proteomic, and metabolomic) data is responsible for the major growth spurt of systems biology. Pharmaceutical companies and others need to make sense out of all this omic information in order to take the next step in overcoming their innovation deficits. Systems biology provides the methods, computational capabilities, and inter-disciplinary expertise to facilitate this jump.
Commercial applications are emerging at an accelerating pace as pharmaceutical and biotechnology research organizations start to combine various forms of omic data into more comprehensive computer models, and bioinformatics companies increasingly turn their attention toward offering systems biology solutions to drug developers and diagnostics companies.
Scope
This Report describes the current state and future prospects of the rapidly developing systems biology field.
The Systems Biology Report clearly defines what systems biology is and does. An historical overview of the field is provided and the technical and commercial background is detailed. The nature of systems biology is examined in its several manifestations; commercial applications in pharmaceutical, diagnostic, and other business segments; and market dynamics. A series of detailed profiles of companies active in the field is followed by in-depth interviews with six systems biology experts.
Market Opportunities
- Create new paradigms for improved drug target selection based on highly sophisticated predictive computational models of biological systems.
- Expand the quality and sophistication of new biomarkers to enhance the probability that a drug with a good preclinical performance will succeed in human clinical trials and to reduce the costs of drug discovery and development by providing surrogates for subjective endpoints.
- Increase the cost-benefit of diagnostic and therapeutic modalities via the reclassification of diseases in molecular rather than symptomatic or organ-specific terms.
- Gain market leverage through the discovery of new diagnostic markers with vastly enhanced sensitivity and specificity.
Key Reasons to Buy
- Identify commercial opportunities in systems biology within the pharmaceutical, biotech and diagnostics markets via an in-depth assessment of the anticipated revenue distribution among target/biomarker licensing, software sales and services, solution providers, and computer vendors.
- Discover the future possibilities of systems biology and the potential business models for systems biology companies from highly informative interviews with six industry veterans.
- Recognize the full impact of systems biology from an overview of radically new products and services capable of making sense of genome-wide data and bridging the gap between information and knowledge.
- Pinpoint the full market potential for systems biology products and services with an examination of the projected growth through 2008.
- Look inside 18 companies active in systems biology, including their product pipelines, financial standing, technology research & development, alliances, and more.
Customers who bought this item also bought
The Future of Systems Biology: Emerging Technologies and their Impact on Drug Discovery, Development and Diagnostics
Outlook for RNAi, 2007: siRNA and miRNA in Biology, Diagnostics and Therapeutics
Strategic Analysis of the World Computational Biology Markets
Systems Biology in Biotech and Pharma: A New Paradigm for Innovation
Synthetic Biology: An Emerging Tool for Drug Discovery and Production
Synthetic Biology, A New Paradigm For Biological Discovery
Fluorine in Medicinal Chemistry and Chemical Biology
Annual Plant Reviews, Volume 35, Plant Systems Biology
Microfluidic Applications in Biology: From Technologies to Systems Biology
Legal Imperatives on Intellectual Property Management
Nanotechnology - World R&D Report 2008 - Research in Medicine and Biology Nanoscience and Nanotechnology
Medaka: Biology, Management, and Experimental Protocols
|
|
|
|
